Dignify Therapeutics

Dignify Therapeutics Announces the Appointment of Anthony DiTonno as Executive Chairman of the Board of Directors

RESEARCH TRIANGLE PARK, NC (RTP) – June 27, 2022 – Dignify Therapeutics (Dignify), developers of novel treatments for bladder and bowel disorders, is pleased to announce that Anthony DiTonno has joined Dignify Therapeutics as Executive Chairman of the Board of Directors, where he will be integral in guiding Dignify’s future drug development and partnering strategies.

Mr. DiTonno is a veteran pharmaceutical executive, with over 25 years of senior leadership experience spanning the pharmaceutical, biotechnology and medical device industries. He most recently served as CEO of Tenax Therapeutics (TENX), Avantis Medical Systems, and NeurogesX (NGSX). He successfully completed one IPO, raised over $200M for previous companies, and secured multiple commercial and corporate partnerships.

Dr. Ed Burgard, President of Dignify, stated, “Tony brings a wealth of corporate development and growth experience to Dignify. As Dignify transitions to a multidimensional therapeutics company with a diverse pipeline of drugs and medical devices, Tony’s guidance will ensure that the company secures the capital and partnerships necessary to advance our novel treatments to patients.”

Mr. DiTonno responded, “I am excited to work with the Dignify team to move these important products forward. The team at Dignify have a wealth of experience in discovery and development of novel bowel and bladder therapies and I am honored to join their Board of Directors.”

About Dignify Therapeutics LLC

Founded by a team of serial entrepreneurs who are internationally-recognized scientists and clinicians, Dignify Therapeutics’ mission is to provide safe, effective, practical and convenient, treatments for bladder and bowel voiding dysfunctions, primarily using a repositioning strategy of drug discovery that the team has successfully implemented multiple times over the last 20 years in the fields of urology and gastroenterology. The Company is funded through venture capital (RA Capital Mgmt and Eshelman Ventures), angel investors, the NIH, the North Carolina Biotechnology Center and the One NC Small Business Program. Dignify Therapeutics is located at the First Flight Venture Center in Research Triangle Park, North Carolina.

This content is solely the responsibility of Dignify Therapeutics and does not necessarily represent the official views of the NIH.

PRESS CONTACT

Dignify Therapeutics

Ed Burgard

P.O. Box 13169

2 Davis Drive

Research Triangle Park, NC 27709

Phone: 919-371-8138

Email: eburgard@dignifytherapeutics.com

Website: https://dignifytherapeutics.com